SequelSEC

Kymera Therapeutics, Inc. KYMR

Biological Products, (No Diagnostic Substances) · CIK 0001815442 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$39.21M
Fiscal year ended 2025-12-31
Operating income
-$349.40M
Fiscal year ended 2025-12-31
Free cash flow
-$234.34M
Fiscal year ended 2025-12-31

Kymera Therapeutics, Inc. (KYMR) reported revenue of $39.21M and net income of -$311.35M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Kymera Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Kymera Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$39.21M$47.07M$78.59M$46.83M$72.83M$34.03M$2.93M
Cost of revenue$39.21M$47.07M$78.59M$46.83MUnavailableUnavailableUnavailable
Gross profit$0$0$0$0UnavailableUnavailableUnavailable
Operating income-$349.40M-$261.64M-$165.53M-$161.26M-$100.53M-$46.30M-$42.20M
Net income-$311.35M-$223.86M-$146.96M-$154.81M-$100.22M-$45.59M-$41.25M
Research & development$316.57M$240.25M$189.08M$164.25M$137.02M$62.10M$37.16M
Weighted-average diluted sharesshares 84.49Mshares 75.04Mshares 58.37Mshares 53.93Mshares 47.99Mshares 17.35MUnavailable
Pretax income-$311.35MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0UnavailableUnavailable$0$0$0$0
Diluted EPS$-3.69$-2.98$-2.52$-2.87$-2.09$-3.15Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$68.19M$63.53M$55.04M$43.83M$36.34M$18.23M$7.98M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Kymera Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$357.01M$120.26M$109.97M$68.40M$47.98M$31.00M$76.02M
Total assets$1.74B$978.04M$575.76M$603.13M$605.90M$487.18M$116.70M
Current assets$871.21M$510.27M$405.32M$419.42M$451.27M$302.34M$92.84M
Total liabilities$163.15M$142.42M$180.79M$112.98M$146.27M$203.29M$82.03M
Current liabilities$83.21M$67.77M$85.69M$71.34M$92.54M$110.62M$34.57M
Total equity incl. NCI$1.58B$835.62M$394.97M$490.15M$459.64M$283.89M-$74.41M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$0$0$15.00M$0UnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$4.02M$5.99M$7.08M$4.34M$4.00M$4.37M$3.28M

Cash flow

Kymera Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$232.89M-$194.50M-$102.83M-$153.08M-$128.95M$88.13M$17.90M
Capital expenditures$1.45M$12.84M$34.48M$2.84M$1.60M$9.10M$532.00K
Investing cash flow-$521.06M-$404.08M$139.89M$20.52M-$99.84M-$422.59M-$16.49M
Financing cash flow$990.71M$608.85M$4.19M$153.00M$250.28M$289.26M$34.91M
Net change in cash$236.76M$10.27M$41.25M$20.43M$21.50M-$45.20M$36.33M
Stock-based compensation$59.90M$55.01M$43.12M$35.48M$24.97M$5.19M$1.20M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$8.31M$7.37M$3.56M$2.98M$2.40M$1.76M$825.00K

Derived

Kymera Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flow-$234.34M-$207.34M-$137.31M-$155.92M-$130.54M$79.03M$17.37M
Gross margin0.0%0.0%0.0%0.0%UnavailableUnavailableUnavailable
Operating margin-891.1%-555.8%-210.6%-344.4%-138.0%-136.1%-1438.5%
FCF margin-597.6%-440.5%-174.7%-333.0%-179.2%232.2%592.1%
SBC / revenue152.8%116.9%54.9%75.8%34.3%15.2%40.8%
Current ratio10.47x7.53x4.73x5.88x4.88x2.73x2.69x
Revenue YoY growth-16.7%-40.1%67.8%-35.7%114.0%1060.0%Unavailable
Net margin-794.0%-475.6%-187.0%-330.6%-137.6%-134.0%-1405.8%
R&D / revenue807.3%510.4%240.6%350.8%188.1%182.5%1266.5%
CapEx / revenue3.7%27.3%43.9%6.1%2.2%26.7%18.1%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open KYMR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-04-30View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2019-12-31

Difference 109080000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.